Vardenafil (Levitra/Staxyn) and Autoimmune Disease: What Clinicians and Patients Need to Know

Vardenafil is a selective phosphodiesterase type 5 (PDE5) inhibitor sold as Levitra (film-coated tablet, 5 to 20 mg) and Staxyn (orally disintegrating tablet, 10 mg). It is FDA-approved only for erectile dysfunction in adult men. It is not approved for female sexual dysfunction and has no autoimmune-disease indication of its own. This article addresses how autoimmune disease and its treatments change the risk-benefit calculation for a man who is otherwise a candidate for a PDE5 inhibitor.

Why autoimmune disease changes the prescribing decision

Erectile dysfunction is reported more often by men with autoimmune disease than by age-matched men generally. Plausible mechanisms include endothelial injury from vascular autoimmunity, autonomic neuropathy, corticosteroid-driven suppression of the hypothalamic-pituitary-gonadal axis, and the psychological burden of chronic illness. None of this is unique to vardenafil, but it means a PDE5 inhibitor is rarely being added to an otherwise simple medication list.

Vardenafil's basic pharmacology is well established: it is a competitive, selective PDE5 inhibitor with oral bioavailability of roughly 15%, a time to peak concentration under an hour, and a half-life of about 4 to 5 hours. It is metabolized primarily by hepatic CYP3A4, with a minor contribution from CYP3A5 and CYP2C9. That single fact, hepatic CYP3A4 clearance, drives most of the clinically important interactions covered below, because many autoimmune treatment regimens include a strong CYP3A4 inhibitor.

The direct answer, with its boundary: vardenafil is not contraindicated by lupus, rheumatoid arthritis, multiple sclerosis, Sjögren syndrome, inflammatory bowel disease, or systemic sclerosis on their own. The prescribing risk in these conditions comes from three overlapping factors, autonomic neuropathy that magnifies vardenafil's normal blood-pressure-lowering effect, concomitant strong CYP3A4 inhibitors that raise vardenafil blood levels, and baseline cardiovascular risk that autoimmune disease itself accelerates, not from a disease-specific pharmacologic incompatibility. This framing is supported by vardenafil's FDA labeling on CYP3A4 interactions and nitrate contraindication; the disease-specific prevalence and mechanism claims below are drawn from the general rheumatology and neurology literature and should be treated as background rather than as precisely quantified figures until verified against the primary papers.

A note on how this draft was built: several numeric claims in earlier versions of this article (exact prevalence percentages, specific trial results, precise pharmacokinetic multipliers) were attached to citations that could not be verified as matching the stated claim. Rather than repeat unverifiable numbers, this version states those claims in general terms and flags where a clinician should check the primary literature or current FDA labeling before relying on a specific figure.

Systemic lupus erythematosus: vascular, renal, and drug-interaction considerations

Lupus can affect the endothelium, kidneys, and autonomic nervous system, and each of those has a plausible bearing on PDE5 inhibitor use.

Endothelial dysfunction and hypotension risk

Antiphospholipid antibodies and vascular inflammation can damage endothelium in some patients with SLE. Because PDE5 inhibitors depend on endothelial nitric oxide production for their effect, efficacy may be reduced in patients with significant lupus vasculitis, though this has not been formally studied for vardenafil specifically. Separately, autonomic neuropathy is a recognized complication of SLE and predisposes patients to orthostatic hypotension. Vardenafil produces a modest reduction in blood pressure at therapeutic doses; in a patient with autonomic instability, that reduction can be clinically more significant than in a patient with an intact baroreflex. This is a plausible, mechanism-based caution rather than a quantified, autoimmune-specific finding.

Lupus nephritis and drug clearance

Lupus nephritis is common over the disease course. Vardenafil is cleared hepatically rather than renally, so mild-to-moderate renal impairment does not by itself require a vardenafil dose change. Severe renal impairment has not been well studied for vardenafil, and the FDA label recommends caution in that setting. Clinicians should check current labeling before prescribing to a patient with an eGFR under 30 mL/min/1.73m².

Hydroxychloroquine

Hydroxychloroquine, used in most SLE patients, is not a meaningful CYP3A4 inhibitor and has no established pharmacokinetic interaction with vardenafil. Hydroxychloroquine carries a small QT-prolonging effect, and vardenafil has its own modest effect on the QT interval at standard doses. Combining two QT-prolonging drugs in a patient who also has electrolyte disturbance from nephritis is a reasonable trigger for a baseline ECG, even without a documented pharmacokinetic interaction.

Rheumatoid arthritis: corticosteroids, DMARDs, and cardiovascular risk

Rheumatoid arthritis carries an independently elevated cardiovascular risk, and RA treatment regimens add several interaction vectors worth checking before prescribing vardenafil.

Corticosteroids and hypogonadism

Chronic corticosteroid use can suppress the hypothalamic-pituitary-gonadal axis and lower testosterone in men. Hypogonadism blunts the libido component of sexual function, so a patient with low testosterone may respond incompletely to a PDE5 inhibitor alone; checking a testosterone level before or during treatment is reasonable in men on long-term steroids. Corticosteroids also raise blood pressure, which in some patients may partially offset vardenafil's hypotensive effect, but this does not remove the need for cardiovascular risk assessment.

Methotrexate and leflunomide

Neither drug is a meaningful CYP3A4 inhibitor or inducer, and no pharmacokinetic interaction with vardenafil is expected mechanistically. Both carry hepatotoxic potential, and since vardenafil is hepatically cleared, confirming acceptable liver enzymes before prescribing is sensible practice rather than a labeled requirement.

JAK inhibitors (tofacitinib, baricitinib, upadacitinib)

Tofacitinib is a CYP3A4 substrate but not considered a clinically significant inhibitor at approved doses; baricitinib and upadacitinib are likewise not meaningful CYP3A4 inhibitors. No specific vardenafil dose adjustment is indicated for co-administration with these agents based on current labeling and mechanism. Formal interaction studies specific to vardenafil and JAK inhibitors do not appear to exist, so this is a mechanism-based, not trial-confirmed, conclusion.

Cardiovascular risk stratification before prescribing

Cardiology consensus guidance on sexual activity and cardiovascular risk (the Princeton Consensus framework) recommends stratifying men by cardiovascular risk before starting a PDE5 inhibitor, using features such as unstable angina, recent myocardial infarction, uncontrolled hypertension, and advanced heart failure. RA accelerates coronary disease, so a patient's chronological age can understate his functional cardiovascular risk. An exercise tolerance test before starting vardenafil is a reasonable consideration in sedentary RA patients with multiple cardiovascular risk factors, at clinician judgment.

Multiple sclerosis: neurogenic erectile dysfunction and autonomic instability

MS can cause erectile dysfunction through spinal cord demyelination interrupting parasympathetic outflow, cortical lesions affecting arousal, and fatigue-related libido suppression. This is generally described as a neurogenic mechanism rather than a primarily vascular one.

PDE5 inhibitor efficacy in neurogenic ED

Randomized trial evidence supporting PDE5 inhibitors in MS-related erectile dysfunction exists for sildenafil, not specifically for vardenafil. Because both drugs act on the same nitric oxide-cGMP pathway, a class effect is plausible, but this is an inference, not a vardenafil-specific finding, and readers should not treat sildenafil trial results as vardenafil trial results. Any claim about vardenafil's PDE6 selectivity being clinically advantageous for patients with optic neuritis is theoretical and has not been tested in a trial; it should not guide drug choice on its own.

Autonomic instability

Autonomic dysfunction occurs in a meaningful minority of MS patients with significant disability, particularly with cervical spinal cord involvement, and can produce unpredictable blood-pressure responses. Starting at the lowest available vardenafil dose in patients with more advanced MS disability, rather than a standard starting dose, is a reasonable precaution, with in-office or home blood-pressure monitoring after the first dose.

Interferons and glatiramer acetate

Interferon beta-1a, interferon beta-1b, and glatiramer acetate do not inhibit hepatic CYP enzymes and are not expected to interact pharmacokinetically with vardenafil.

Biologics and immunosuppressants: the CYP3A4 interaction map

The most clinically important vardenafil interactions in autoimmune patients come from immunosuppressants that are potent CYP3A4 inhibitors, because vardenafil is cleared through that same pathway.

Calcineurin inhibitors: cyclosporine and tacrolimus

Cyclosporine is a strong CYP3A4 inhibitor used in lupus nephritis, RA, and psoriatic arthritis. The FDA vardenafil label specifies a substantial dose reduction when vardenafil is co-administered with strong CYP3A4 inhibitors; clinicians should consult the current label for the exact dose cap rather than rely on a remembered number, since labeling can be updated. Tacrolimus has weaker CYP3A4 inhibitory activity than cyclosporine, and a conservative, reduced starting dose is a reasonable approach when tacrolimus is part of the regimen, pending label confirmation.

Azathioprine and mycophenolate mofetil

Neither is a CYP3A4 inhibitor, and neither is expected to require a vardenafil dose adjustment on pharmacokinetic grounds. Both can cause mild hepatotoxicity, which is a reason to check liver function rather than a reason to adjust dose specifically for a drug interaction.

TNF-alpha inhibitors

Adalimumab, etanercept, and infliximab are large-molecule biologics cleared through immunoglobulin catabolism, not CYP pathways. No pharmacokinetic interaction with vardenafil is expected, and none is described in vardenafil's labeling.

Rituximab

Rituximab is cleared through immunoglobulin catabolism and does not affect CYP3A4. Transient blood-pressure changes can occur during a rituximab infusion, but this does not represent a chronic interaction with vardenafil taken on an as-needed basis days or weeks later.

Inflammatory bowel disease and spondyloarthropathies

IBD and absorption variability

Active Crohn's disease or ulcerative colitis affecting the small bowel could plausibly impair absorption of an oral tablet, since vardenafil's standard formulation is absorbed through the gastrointestinal tract. The orally disintegrating Staxyn tablet dissolves in the mouth, but its active drug is still absorbed systemically rather than through the oral mucosa in a way that bypasses gut absorption, so it should not be assumed to solve an absorption problem caused by bowel disease. This is a mechanistic consideration rather than a studied clinical finding for vardenafil specifically.

Ankylosing spondylitis and psoriatic arthritis

Erectile dysfunction is reported at elevated rates in ankylosing spondylitis compared with the general population; exact prevalence figures vary across studies and should be checked against a current source before being quoted precisely. Spinal involvement in advanced disease may add a neurogenic component. Commonly used NSAIDs in AS (naproxen, indomethacin) are not CYP3A4 inhibitors and are not expected to interact with vardenafil.

Sjögren syndrome and systemic sclerosis

Sjögren syndrome

Small-fiber autonomic neuropathy affecting cardiovascular regulation has been described in Sjögren syndrome. As with lupus and MS, this creates a lower threshold for vardenafil-related symptomatic hypotension in affected patients, supporting a lower starting dose with blood-pressure monitoring after the first dose when autonomic involvement is documented or suspected.

Systemic sclerosis (scleroderma)

PDE5 inhibitors as a class have an established, guideline-recognized role in SSc-related Raynaud phenomenon and pulmonary arterial hypertension; sildenafil and tadalafil carry specific FDA approvals for PAH under different brand names. Vardenafil does not carry an FDA-approved PAH indication, and using it for Raynaud's or PAH in scleroderma would be off-label. If a patient with SSc-PAH is on bosentan or a prostacyclin analogue, additive hypotension is a real concern, and bosentan is a CYP3A4 inducer, which could lower vardenafil levels rather than raise them. Dose adjustment in that combination should follow individualized clinical judgment and current labeling, not a fixed rule.

Absolute contraindications and high-risk combinations

Vardenafil autoimmune prescribing decision framework

Because no single autoimmune diagnosis is itself a contraindication, the prescribing decision is really a sequence of smaller checks. This framework orders them from hard stop to fine-tuning, so a clinician or patient can see which factor should change the plan at each step.

If steps 1 through 5 raise no concern, standard dosing and a routine follow-up plan are reasonable. If more than one intermediate factor applies (for example, moderate CYP3A4 inhibition plus autonomic neuropathy), the more conservative dose and closer monitoring interval should govern, since these risks are additive rather than independent.

Nitrates (absolute contraindication): Organic nitrates and nitrite inhalants ("poppers") are absolutely contraindicated with all PDE5 inhibitors, autoimmune diagnosis notwithstanding. The FDA label states this contraindication without exception.

Riociguat (absolute contraindication): The soluble guanylate cyclase stimulator riociguat, sometimes used in pulmonary hypertension including SSc-PAH, is absolutely contraindicated with vardenafil per FDA labeling.

Alpha-1 blockers: Tamsulosin and similar drugs, used for lower urinary tract symptoms, can produce additive hypotension with vardenafil. Label-recommended dose separation and a conservative starting dose apply.

Strong CYP3A4 inhibitors: Voriconazole and itraconazole, used for fungal infections in immunosuppressed autoimmune patients, are potent CYP3A4 inhibitors requiring the same dose caution as cyclosporine and ritonavir. Confirm the current numeric dose cap against the FDA label rather than relying on a remembered figure, since exact multipliers reported in older pharmacokinetic studies vary by drug and by dose of the inhibitor.

Dosing guidance for autoimmune patients

Standard vardenafil dosing is 10 mg taken 25 to 60 minutes before sexual activity, with a labeled range of 5 to 20 mg and a maximum frequency of once daily. The adjustments below reflect the reasoning above; they are general guidance, not individualized dosing instructions, and the treating clinician should confirm against current labeling and the patient's full picture.

Monitoring and follow-up in autoimmune patients

Autoimmune patients prescribed vardenafil benefit from structured follow-up rather than a single prescription with no check-in, given their comorbidity burden.

Baseline assessment

Before the first prescription: confirm blood pressure is reasonably controlled, confirm absence of nitrate or riociguat use, review the full medication list for CYP3A4 inhibitors, consider a resting ECG if other QT-prolonging drugs are present, and check liver function if the patient is on a hepatotoxic DMARD. A testosterone level is reasonable in men on chronic corticosteroids, since untreated hypogonadism can blunt the response to a PDE5 inhibitor.

Follow-up

At a follow-up visit, ask about symptom improvement, side effects (headache, flushing, visual changes, dizziness), and any changes to the autoimmune medication regimen. If a patient reports no benefit at a mid-range dose after several attempts, dose titration toward the upper labeled range is reasonable before concluding the drug has failed, subject to the cardiovascular and interaction checks above.

Periodic review

Autoimmune disease activity changes over time. A patient who was cardiovascularly stable when vardenafil was started may later develop lupus nephritis, cardiac involvement in scleroderma, or worsening autonomic dysfunction in MS. Periodic review of the prescribing rationale, cardiovascular risk, and medication list is reasonable, though no formal interval is established specifically for this population.

Vardenafil in women with autoimmune disease

Vardenafil is not FDA-approved for female sexual dysfunction, and evidence in women is limited. Women with SLE or systemic sclerosis do report significant sexual dysfunction, including reduced arousal and dyspareunia, but this reflects the underlying disease burden rather than evidence that vardenafil treats it. Off-label use of vardenafil in women, with or without autoimmune disease, is not supported by adequate clinical trial evidence and is not addressed by current FDA labeling.

What is established, what is plausible, and what is not established

Established: vardenafil is metabolized by hepatic CYP3A4; strong CYP3A4 inhibitors raise vardenafil blood levels and require dose reduction per FDA labeling; nitrates and riociguat are absolute contraindications; vardenafil is not FDA-approved for women or for pulmonary arterial hypertension.

Plausible but not established for vardenafil specifically: that PDE5 inhibitors help neurogenic erectile dysfunction in MS (shown for sildenafil, inferred for vardenafil by mechanism); that vardenafil's PDE6 selectivity offers a meaningful clinical advantage for patients with visual symptoms; that vardenafil helps SSc-related Raynaud phenomenon at ED doses.

Not established: precise prevalence figures for erectile dysfunction across specific autoimmune diagnoses, exact pharmacokinetic interaction magnitudes for every DMARD-vardenafil pairing, and any benefit of vardenafil for female sexual dysfunction in autoimmune disease.

If a specific number, such as an exact prevalence percentage or an exact fold-increase in drug exposure, matters to a clinical decision, it should be confirmed against the current FDA label or a verified primary source before being used, rather than taken from this summary.

This article was drafted for editorial and qualified medical review and has not yet received that review. Numeric claims flagged above as unverified should be checked against primary literature or current FDA labeling before clinical use. This content does not provide individualized dosing or diagnosis and is not a substitute for a clinician who knows the patient's full history. Seek urgent care for symptoms such as sudden vision loss, chest pain, an erection lasting more than four hours, or symptomatic hypotension after taking vardenafil.